Dynavax projects HEPLISAV-B revenue of $305M-$325M for 2025 amid expanding hepatitis B market Dynavax projects HEPLISAV-B revenue of $305M-$325M for 2025 amid expanding hepatitis B market Post ContentdvaxRead More You might also be interested in reading Tether signs MoU to promote crypto freedom in Turkey. February 20, 2025 In Mainstream ← Previous post Next post →